|
2012-09-17 |
iorEPOCIM-Stroke-Phase I |
CIMAB |
Registered outdated |
|
2011-05-19 |
Perioperative administration of probiotics-colorectal cancer-operated by laparoscopy. |
CNCMA |
Registered outdated |
|
2009-07-03 |
Safety evaluation of Recombinant Human Erythropoietin ior EPOCIM in the treatment of patient with cerebral infarction acute. Study Stage I. |
CIMAB |
Registered outdated |
|
2013-06-14 |
Pneumococcal conjugate vaccination among Warao children |
SAIB |
Registered outdated |
|
14/12/2015 |
CIMAvax-EGF vaccine Predictor Phase IV |
CIM |
Registered outdated |
|
12/11/2021 |
BACONAO Study |
CIGB |
Registered outdated |
|
28/09/2021 |
SOBERANA PLUS PEDIATRIA |
FINLAY |
Registered outdated |
|
14/06/2018 |
Subcutaneous immunotherapy with PROLINEM-DS-Asthma- Adults-Fase II |
BIOCEN |
Registered outdated |
|
13/05/2020 |
PrevengHo-Vir Homeoprohylaxis COVID-2019 |
MINSAP_MNT |
Registered outdated |
|
22/05/2020 |
Evaluation of the synergistic effect of sequential administration of two immunostimulant products: Immuno-1 and Immuno-2 for the stimulation of the immune response in older adults. Exploratory study |
FINLAY |
Registered outdated |
|
12/05/2020 |
Treatment of SARS CoV-2 pneumonia with the anti-CD6 monoclonal antibody itolizumab |
CIM |
Registered outdated |
|
05/06/2020 |
Rectal Ozone in the COVID-19 treatment |
CPN |
Registered outdated |
|
15/08/2018 |
Evaluation of Biomodulin T® in patients with HIV/AIDS. Phase II/III. |
BIOCEN |
Registered outdated |
|
07/12/2016 |
NGcGM3/VSSP in small cell lung cancer |
CIM |
Registered outdated |
|
26/08/2013 |
ior ®EPOCIM as a cardioprotective agent in the surgery of rheumatic valvular disease. |
CIMAB |
Registered outdated |
|
05/11/2013 |
RituxCIM in relapsed or refractory indolent B-cell non-Hodgkin lymphoma |
CIM |
Registered outdated |
|
09/07/2020 |
Zinc-Children-Hospitalized-Pneumonia |
SAHUAPA |
Registered outdated |
|
09/07/2020 |
Second Line-Acute Asthma |
SAHUAPA |
Registered outdated |
|
28/04/2017 |
Safety and immunogenicity of VCN7-T in infants of 2 and 3 months. Phase I/II. |
FINLAY |
Registered outdated |
|
14/04/2020 |
ESPERANZA study |
CIGB |
Registered outdated |
